<SEC-DOCUMENT>0001104659-24-085098.txt : 20240802
<SEC-HEADER>0001104659-24-085098.hdr.sgml : 20240802
<ACCEPTANCE-DATETIME>20240802070019
ACCESSION NUMBER:		0001104659-24-085098
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240801
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240802
DATE AS OF CHANGE:		20240802

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adaptimmune Therapeutics PLC
		CENTRAL INDEX KEY:			0001621227
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37368
		FILM NUMBER:		241168812

	BUSINESS ADDRESS:	
		STREET 1:		60 JUBILEE AVENUE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RX
		BUSINESS PHONE:		44 1235 430000

	MAIL ADDRESS:	
		STREET 1:		60 JUBILEE AVENUE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RX

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Adaptimmune Ltd
		DATE OF NAME CHANGE:	20141001
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2420733d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:adap="http://adaptimmune.com/20240801">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03B_adap_adaptimmune.com_20240801 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20240801_20240801 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0001621227 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-08-01" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-08-01" id="Fact000004" name="dei:EntityCentralIndexKey">0001621227</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-08-01" id="xdx2ixbrl0014" name="dei:EntityTaxIdentificationNumber">00-0000000</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="adap-20240801.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-08-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001621227</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-01</xbrli:startDate>
        <xbrli:endDate>2024-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<div style="display: none">

</div>


<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES<br/>
SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 18pt"><b>FORM
<span id="xdx_907_edei--DocumentType_c20240801__20240801_zCNGBmhFAgPf"><ix:nonNumeric contextRef="AsOf2024-08-01" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Current Report</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):<b>
<span id="xdx_90E_edei--DocumentPeriodEndDate_c20240801__20240801_znEuoCzppwZ3"><ix:nonNumeric contextRef="AsOf2024-08-01" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">August 1, 2024</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_908_edei--EntityRegistrantName_c20240801__20240801_zuxvcYryLwSh"><ix:nonNumeric contextRef="AsOf2024-08-01" id="Fact000011" name="dei:EntityRegistrantName">ADAPTIMMUNE THERAPEUTICS PLC</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its
charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90D_edei--EntityIncorporationStateCountryCode_c20240801__20240801_zKI6bLZUpcE"><ix:nonNumeric contextRef="AsOf2024-08-01" format="ixt-sec:edgarprovcountryen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">England and Wales</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_907_edei--EntityFileNumber_c20240801__20240801_zZASZo1XegV7"><ix:nonNumeric contextRef="AsOf2024-08-01" id="Fact000013" name="dei:EntityFileNumber">1-37368</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span title="::XDX::00-0000000"><span id="xdx_900_edei--EntityTaxIdentificationNumber_dxL_c20240801__20240801_zqW8PUlzumMc" title="::XDX::00-0000000"><span style="-sec-ix-hidden: xdx2ixbrl0014">Not Applicable</span></span></span></b></span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(State or other jurisdiction of<br/>
incorporation)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Commission File Number)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(IRS Employer Identification No.)</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90B_edei--EntityAddressAddressLine1_c20240801__20240801_zqhRcs17JgB3"><ix:nonNumeric contextRef="AsOf2024-08-01" id="Fact000015" name="dei:EntityAddressAddressLine1">60 Jubilee Avenue</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressAddressLine2_c20240801__20240801_zuGAEIwCPrG"><ix:nonNumeric contextRef="AsOf2024-08-01" id="Fact000016" name="dei:EntityAddressAddressLine2">Milton Park</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90A_edei--EntityAddressCityOrTown_c20240801__20240801_zJ9IHyY3gPtk"><ix:nonNumeric contextRef="AsOf2024-08-01" id="Fact000017" name="dei:EntityAddressCityOrTown">Abingdon, Oxfordshire</ix:nonNumeric></span> <span id="xdx_902_edei--EntityAddressPostalZipCode_c20240801__20240801_zB5McGhw9aff"><ix:nonNumeric contextRef="AsOf2024-08-01" id="Fact000018" name="dei:EntityAddressPostalZipCode">OX14 4RX</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_903_edei--EntityAddressCountry_c20240801__20240801_zcHsc0i7N9Lf"><ix:nonNumeric contextRef="AsOf2024-08-01" format="ixt-sec:countrynameen" id="Fact000019" name="dei:EntityAddressCountry">United Kingdom</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices,
including zip code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_906_edei--CityAreaCode_c20240801__20240801_zMWHbOaA44q7"><ix:nonNumeric contextRef="AsOf2024-08-01" id="Fact000020" name="dei:CityAreaCode">44</ix:nonNumeric></span>) <span id="xdx_905_edei--LocalPhoneNumber_c20240801__20240801_zoxZIztN2hve"><ix:nonNumeric contextRef="AsOf2024-08-01" id="Fact000021" name="dei:LocalPhoneNumber">1235 430000</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including
area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_90E_edei--WrittenCommunications_c20240801__20240801_zpWkVYVt4bAk"><ix:nonNumeric contextRef="AsOf2024-08-01" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span>&#160;</td><td style="text-align: left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_90E_edei--SolicitingMaterial_c20240801__20240801_zryvqzhI0MZ"><ix:nonNumeric contextRef="AsOf2024-08-01" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td><td style="text-align: left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_90B_edei--PreCommencementTenderOffer_c20240801__20240801_z7WRxuYCIQs3"><ix:nonNumeric contextRef="AsOf2024-08-01" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td><td style="text-align: left">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_900_edei--PreCommencementIssuerTenderOffer_c20240801__20240801_zKK16AwPugHh"><ix:nonNumeric contextRef="AsOf2024-08-01" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td><td style="text-align: left">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="vertical-align: bottom; width: 35%; text-align: center"><b>Title of each class</b></td>
    <td style="text-align: center; width: 2%; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; width: 26%; text-align: center"><b>Trading Symbol</b></td>
    <td style="text-align: center; width: 2%; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; width: 35%; text-align: center"><b>Name of each exchange on which <br/>
registered</b></td></tr>
<tr style="text-align: left; vertical-align: bottom">
    <td style="vertical-align: top; text-align: center"><span id="xdx_900_edei--Security12bTitle_c20240801__20240801_zfCzipMT5aN"><ix:nonNumeric contextRef="AsOf2024-08-01" id="Fact000026" name="dei:Security12bTitle">American Depositary Shares, each representing 6 Ordinary Shares, par value &#163;0.001 per share</ix:nonNumeric></span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_901_edei--TradingSymbol_c20240801__20240801_zoLgJx6UM7ql"><ix:nonNumeric contextRef="AsOf2024-08-01" id="Fact000027" name="dei:TradingSymbol">ADAP</ix:nonNumeric></span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_907_edei--SecurityExchangeName_c20240801__20240801_zqiO3gKqkpQ8"><ix:nonNumeric contextRef="AsOf2024-08-01" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company <span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_902_edei--EntityEmergingGrowthCompany_c20240801__20240801_zZVejICSgbDl"><ix:nonNumeric contextRef="AsOf2024-08-01" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 90px; font-size: 10pt"><b>Item&#160;7.01</b></td>
    <td style="font-size: 10pt"><b>Regulation FD Disclosure.</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">On August&#160;1, 2024, Adaptimmune Therapeutics
plc. (the &#8220;<b><i>Company</i></b>&#8221;) issued a press release announcing that the U.S. Food and Drug Administration (the &#8220;<b><i>FDA</i></b>&#8221;)
approved TECELRA&#174; (afamitresgene autoleucel), the first engineered cell therapy for a solid tumor cancer approved in the U.S. TECELRA&#174;
was approved for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P,
-A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion
diagnostic devices. A copy of this press release is furnished as Exhibit&#160;99.1 to this Current Report on Form&#160;8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The furnished under this Item 7.01, including Exhibit&#160;99.1 shall
not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;<b><i>Exchange
Act</i></b>&#8221;), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing
under the&#160;Securities Act of 1933, as amended&#160;(the &#8220;<b><i>Securities Act</i></b>&#8221;) or the&#160;Exchange Act, except
as shall be expressly set forth by reference in such a filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 90px; font-size: 10pt"><b>Item&#160;8.01</b></td>
    <td style="font-size: 10pt"><b>Other Events.</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">As noted in Item 7.01 above, on August&#160;1,
2024, the Company announced that the FDA approved TECELRA&#174; (afamitresgene autoleucel), the first engineered cell therapy for a solid
tumor cancer approved in the U.S., for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior
chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined
by FDA-approved or cleared companion diagnostic devices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Forward Looking Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">This Current Report on Form&#160;8-K&#160;may
contain forward-looking statements made in reliance upon the safe harbor provisions of Section&#160;27A of the Securities Act and Section&#160;21E
of the Securities Exchange Act of 1934, as amended. Forward-looking statements address our expected future business, financial performance,
financial condition, as well as the results of operations and often contain words such as &#8220;anticipate&#8221; &#8220;believe,&#8221;
&#8220;expect,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; and similar expressions. Such
statements are based only upon current expectations of Adaptimmune. Reliance should not be placed on forward-looking statements because
they involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those
indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development
activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization
processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those
expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report
on Form&#160;10-K filed with the Securities and Exchange Commission (&#8220;<b><i>SEC</i></b>&#8221;) for the year ended December&#160;31,
2023, our Quarterly Reports on Form&#160;10-Q, Current Reports on Form&#160;8-K, and other filings with the SEC. The forward-looking statements
contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such
forward-looking statements to reflect subsequent events or circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01 Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following exhibit relating to Item 7.01 shall be deemed to be furnished,
and not filed:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&#160;Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding: 0.25pt; white-space: nowrap; font-size: 10pt; width: 10%"><b><span style="text-decoration: underline">Exhibit&#160;No.</span></b></td>
    <td style="width: 2%">&#160;</td>
    <td style="padding: 0.25pt; font-size: 10pt; width: 88%"><b><span style="text-decoration: underline">Description of Exhibit</span></b></td></tr>
  <tr>
    <td style="padding: 0.25pt; white-space: nowrap; vertical-align: top; font-size: 10pt"><a href="tm2420733d1_ex99-1.htm">99.1</a></td>
    <td>&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><a href="tm2420733d1_ex99-1.htm">Press Release, dated August&#160;1, 2024.</a></td></tr>
  <tr>
    <td style="padding: 0.25pt; white-space: nowrap; vertical-align: top; font-size: 10pt">104</td>
    <td>&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cover Page&#160;Interactive Data File (embedded within the Inline
XBRL document).</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly
authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">ADAPTIMMUNE THERAPEUTICS PLC</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">Date: August&#160;2, 2024</td>
    <td style="font-size: 10pt">By:</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt">/s/ Margaret Henry</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 51%">&#160;</td>
    <td style="font-size: 10pt; width: 4%">&#160;</td>
    <td style="font-size: 10pt; width: 5%">Name:</td>
    <td style="font-size: 10pt; width: 40%">Margaret Henry</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">Title:</td>
    <td style="font-size: 10pt">Corporate Secretary</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2420733d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><IMG SRC="tm2420733d1_ex99-1img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Adaptimmune Receives U.S. FDA Accelerated Approval
of <FONT STYLE="background-color: white">TECELRA<SUP>&reg;</SUP> (afamitresgene autoleucel), the First Approved Engineered Cell Therapy
for a Solid Tumor</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Approved for <FONT STYLE="background-color: white">advanced
MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy</FONT></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>TECELRA is the first new treatment option for
people with synovial sarcoma in more than a decade</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Adaptimmune to hold webcast at <U>https://www.gowebcasting.com/13428&nbsp;</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>on August&nbsp;2, at 8:00 a.m.&nbsp;EDT</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Philadelphia, Pennsylvania and Oxford, United Kingdom &ndash; </B>(BusinessWire).
 &ndash; August&nbsp;1, 2024 - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor
cancers with cell therapy, today announced U.S. Food and Drug Administration (FDA) accelerated approval of TECELRA<SUP>&reg;</SUP> (afamitresgene
autoleucel) for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P,
-A*02:02P, -A*02:03P, or <FONT STYLE="background-color: white">-A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined
by FDA-approved or cleared companion diagnostic devices. This indication is approved under accelerated approval based on overall response
rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical
benefit in a confirmatory trial. </FONT>TECELRA is the first engineered cell therapy for a solid tumor cancer approved in the U.S., and
the first new therapy option in more than a decade for synovial sarcoma, a rare, soft tissue cancer that most commonly impacts young adults.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Adrian Rawcliffe, Adaptimmune's Chief Executive Officer:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;The approval of TECELRA is a momentous step in Adaptimmune&rsquo;s
journey to redefine the way cancer is treated and the culmination of a decade of groundbreaking R&amp;D. I want to thank the patients,
caregivers, investigators, and clinical teams as well as everyone at Adaptimmune and our partners who made possible this watershed moment
for cell therapy and for people with synovial sarcoma. We are committed to advancing our robust clinical pipeline to serve more patients
in need and plan to progress lete-cel, the next late-stage investigational treatment in our sarcoma franchise, with a rolling BLA submission
to the FDA next year.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The approval of TECELRA was based on results of the SPEARHEAD-1 (Cohort
1) trial, which included 44 patients. The major efficacy outcome was overall response rate (ORR) determined by independent review and
supported by duration of response. TECELRA treatment resulted in an ORR of 43% with a complete response rate of 4.5%. The median duration
of response was 6 months (95% CI: 4.6, not reached). Among patients who were responsive to the treatment, 39% had a duration of response
of 12 months or longer.*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Data from the pivotal SPEARHEAD-1 trial were previously published in
The Lancet earlier this year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">With this approval, Adaptimmune is positioned to make a significant
impact on the synovial sarcoma community<FONT STYLE="font-size: 10pt">. </FONT>HCPs can begin testing patients, Adaptimmune systems are
ready to take TECELRA orders, and an <FONT STYLE="background-color: white">integrated
support program, AdaptimmuneAssist, is available to enable a seamless and personalized experience through the treatment journey. Adaptimmune
plans to have at least six to ten authorized treatment centers (ATCs) up and running this year and to onboard approximately 30 treatment
centers within the first two years. These ATCs are recognized leaders in sarcoma research and treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>*Per Kaplan-Meier method</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="tm2420733d1_ex99-1img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Brandi Felser, Chief Executive Officer, Sarcoma Foundation of America:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;For decades, therapeutic options for people diagnosed with synovial
sarcoma have been limited.&nbsp;With a current&nbsp;five-year survival rate as low as 36%, and for those with metastatic disease at diagnosis,
as low as 20%, it is long past time that&nbsp;synovial&nbsp;sarcoma patients have expanded treatment options. Since&nbsp;one third of
patients are diagnosed under age 30,&nbsp;improved&nbsp;outcomes&nbsp;can have a tremendous impact.&nbsp;Today, there is a renewed sense
of hope for this patient community.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Sandra D&rsquo;Angelo, MD, Sarcoma Medical Oncologist and Cell
Therapist, Memorial Sloan Kettering Cancer Center; SPEARHEAD Trial Principal Investigator:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>&ldquo;TECELRA (afami-cel), which uses
each patient&rsquo;s own immune cells to recognize and attack their cancer cells in a one-time infusion treatment, is significantly different
than the current standards of care for advanced synovial sarcoma. This approval represents a much-needed new option for people diagnosed
with this sarcoma and an important milestone for the use of cell therapies in solid tumor cancers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TECELRA is contraindicated in adults who are heterozygous or homozygous
for HLA-A*02:05P.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TECELRA can cause serious side effects, including cytokine release
syndrome (CRS), immune effector cell&ndash;associated neurotoxicity syndrome (ICANS), prolonged severe cytopenia, infections, secondary
malignancies, and hypersensitivity reactions. Most common adverse reactions (incidence &ge;20%) were CRS, nausea, vomiting, fatigue, infections,
pyrexia, constipation, dyspnea, abdominal pain, non-cardiac chest pain, decreased appetite, tachycardia, back pain, hypotension, diarrhea,
edema, low white blood cells, low red blood cells and low platelets. <B>Please see Important Safety Information, including Boxed Warning
below.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Biomarker tests for human leukocyte antigens (HLA) type and melanoma-associated
antigen A4 (MAGE-A4) tumor expression are required prior to treatment with TECELRA. Adaptimmune has partnered with Agilent Technologies
for the development, manufacturing, and supply of a companion diagnostic for the MAGE-A4 biomarker, MAGE-A4 IHC 1F9 pharmDx, which also
received approval today from the U.S. FDA and is now available. Additionally, the company partnered with Thermo Fisher Scientific to expand
the labeling of Thermo Fisher&rsquo;s companion diagnostic product SeCore<SUP>TM</SUP> CDx HLA-A Locus Sequencing System to include TECELRA
and to aid in the identification of HLA-A*02:01, A*02:02, A*02:03, and A*02:06-positive patients with synovial sarcoma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For more information about TECELRA visit www.adaptimmune.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Conference Call Details</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company will host a live webcast to provide additional details
tomorrow, August&nbsp;2, 8:00 a.m.&nbsp;EDT. A live webcast of the conference call and replay can be accessed here: <U>https://www.gowebcasting.com/13428</U>.
Call in information is as follows: <B>1-844-763-8274 (TOLL FREE US or Canada) or +1-647-484-8814 (International)</B> and <FONT STYLE="font-size: 10pt">additional
</FONT>options available <U>HERE</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="tm2420733d1_ex99-1img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Synovial Sarcoma</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There are more than 50 different types of soft tissue sarcomas which
are categorized by tumors that appear in fat, muscle, nerves, fibrous tissues, blood vessels, or deep skin tissues.<FONT STYLE="font-size: 10pt"><SUP>1
</SUP></FONT>Synovial sarcoma accounts for approximately 5 to 10% of all soft tissue sarcomas (there are approximately 13,400 new soft
tissue cases in the U.S. each year).<SUP>1,<FONT STYLE="font-size: 10pt">2</FONT></SUP> One third of patients with synovial sarcoma will
be diagnosed under the age of 30.<SUP>2 </SUP>The five-year survival rate for people with metastatic disease is approximately 20% and
most people undergoing standard of care treatment for advanced disease experience recurrence and go through multiple lines of therapy,
often exhausting all options.<SUP>1,<FONT STYLE="font-size: 10pt">3</FONT></SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About TECELRA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TECELRA&reg; (afamitresgene autoleucel) is a melanoma-associated antigen
A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adults with unresectable or
metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose
tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This indication is approved under accelerated approval based on overall
response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of
clinical benefit in a confirmatory trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>IMPORTANT SAFETY INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CONTRAINDICATION: DO NOT use TECELRA in adults who are heterozygous
or homozygous for HLA-A*02:05P.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>BOXED WARNING: Cytokine release syndrome (CRS), which may be severe
or life-threatening, occurred in patients receiving TECELRA. At the first sign of CRS, immediately evaluate patient for hospitalization
and institute treatment with supportive care. Ensure that healthcare providers administering TECELRA have immediate access to medications
and resuscitative equipment to manage CRS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CRS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">CRS occurred in 75% of patients (2% Grade &ge;3) with a median onset of 2
days (range: 1 to 5 days) and median resolution of 3 days (range: 1 to 14 days). CRS (including Grade 1) was managed with tocilizumab
in 55% of patients who experienced CRS.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">In patients who experienced CRS, the most common symptoms included fever,
tachycardia, hypotension, nausea/vomiting, and headache.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. &ldquo;What is a Soft Tissue Sarcoma?&rdquo; American Cancer Society.
<U>https://www.cancer.org/cancer/types/soft-tissue-sarcoma/about/soft-tissue-sarcoma.html</U>. Accessed June 24, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2. &ldquo;Soft Tissue Sarcoma.&rdquo; Cleveland Clinic. <U>https://my.clevelandclinic.org/health/diseases/21732-soft-tissue-sarcoma</U>.
Accessed June 24, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3. Jami SA, Mobarak SA, Jiandang S, et al. Clinical and strategic
outcomes of metastatic synovial sarcoma on limb. <I>Int J Health Sci(Qassim)</I>. 2020;14:38&ndash;43.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="tm2420733d1_ex99-1img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Immune Effector Cell&ndash;associated Neurotoxicity Syndrome (ICANS)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">ICANS has been observed following administration of TECELRA. One patient
(2%) had Grade 1 ICANS with a median onset of 2 days and resolution of 1 day.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">ICANS symptoms can include mental status changes, disorientation to time
and place, drowsiness, inattention, altered level of consciousness, seizures, cerebral edema, impairment of cognitive skills, progressive
aphasia, and motor weakness.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Advise patients to refrain from driving and engaging in hazardous occupations
or activities, such as operating heavy machinery or potentially dangerous machinery for 4 weeks following infusion due to the potential
for neurologic events, including dizziness and presyncope.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Monitoring for CRS and ICANS During and Following TECELRA Infusion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Ensure that healthcare providers administering TECELRA have immediate access
to medications and resuscitative equipment to manage CRS and ICANS. Ensure patients are euvolemic prior to initiating TECELRA.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">During and following TECELRA administration, closely monitor patients for
signs and symptoms of CRS and ICANS. Following treatment with TECELRA, monitor patients for at least 7 days at the healthcare facility.
Continue to monitor patients for at least 4 weeks following treatment with TECELRA. Counsel patients to seek medical attention should
signs or symptoms of CRS or ICANS occur.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">At the first sign of CRS or ICANS, immediately evaluate patients for hospitalization
and administer supportive care based on severity and consider further management per clinical practice guidelines.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Prolonged Severe Cytopenia</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Anemia, neutropenia, and/or thrombocytopenia can occur for several weeks
following lymphodepleting chemotherapy and TECELRA infusion. Patients with Grade &ge;3 cytopenia not resolved by week 4 included anemia
(9%), neutropenia (11%), and thrombocytopenia (5%). The median time to resolution was 7.3 weeks (range: 6.1 to 8.4 weeks) for anemia,
9.3 weeks (range: 6.4 to 12.3 weeks) for neutropenia, and 6.3 weeks (range: 6.1 to 6.4 weeks) for thrombocytopenia.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Monitor blood counts after TECELRA infusion. Manage cytopenia with growth
factor and blood product transfusion according to clinical practice guidelines.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Infections</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Infections may occur following lymphodepleting chemotherapy and TECELRA infusion
and occurred in 32% of patients (14% Grade 3).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Do not administer TECELRA to patients with active infections and/or inflammatory
disorders.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Monitor patients for signs and symptoms of infection before and after TECELRA
infusion and treat patients appropriately.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Febrile neutropenia was observed in patients after TECELRA infusion and may
be concurrent with CRS. In the event of febrile neutropenia, evaluate for infection and manage with broad-spectrum antibiotics, fluids,
and other supportive care, as medically indicated.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Viral reactivation has occurred in patients following TECELRA. Perform screening
for Epstein-Barr virus, cytomegalovirus, hepatitis B virus, hepatitis C virus, and human immunodeficiency virus (HIV) or any other infectious
agents if clinically indicated. Consider antiviral therapy to prevent viral reactivation per local guidelines.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Secondary Malignancies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Patients treated with TECELRA may develop secondary malignancies or recurrence
of their cancer. Monitor for secondary malignancies.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="tm2420733d1_ex99-1img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Hypersensitivity Reactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Serious hypersensitivity reactions, including anaphylaxis, may occur due
to dimethyl sulfoxide (DMSO) in TECELRA. Observe patients for hypersensitivity reactions during infusion.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Potential for HIV Nucleic Acid Test False-Positive Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">The lentiviral vector used to make TECELRA has limited, short spans of genetic
material that are identical to HIV. Therefore, some commercial HIV nucleic acid tests may yield false-positive results in patients who
have received TECELRA.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Adverse Reactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Most common adverse reactions (incidence &ge;20%) are CRS, nausea, vomiting,
fatigue, infections, pyrexia, constipation, dyspnea, abdominal pain, non-cardiac chest pain, decreased appetite, tachycardia, back pain,
hypotension, diarrhea, and edema.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Most common Grade 3 or 4 laboratory abnormalities (incidence &ge;20%) were
lymphocyte count decreased, neutrophil count decreased, white cell blood count decreased, red blood cell decreased, and platelet count
decreased.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Most common serious adverse reactions (&ge;5%) were CRS and pleural effusion.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Please see full <U>Prescribing Information</U>, including Boxed
Warning and <U>Medication Guide<FONT>.</FONT></U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About AdaptimmuneAssist</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">An integrated support program, AdaptimmuneAssist is now available to
provide access support for patients, their caregivers, and healthcare providers throughout the TECELRA treatment journey. AdaptimmuneAssist
includes connection with a Treatment Navigator, travel and financial support programs for eligible patients, and access to the AdaptimmuneAssist
Order Portal (for healthcare providers only). For more information, physicians and patients may call 1-855-246-9232 or visit www.adaptimmuneassist.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Adaptimmune</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Adaptimmune is a fully integrated cell therapy company working to redefine
how cancer is treated. With its unique engineered T cell receptor (TCR) platform, the Company is developing personalized medicines designed
to target and destroy difficult-to-treat solid tumor cancers and improve the patient&rsquo;s cancer treatment experience.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B></B>This release
contains &quot;forward-looking statements&quot; within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). Forward-looking
statements address our expected future business, financial performance, financial condition, as well as the results of operations and
often contain words such as &ldquo;anticipate&rdquo; &ldquo;believe,&rdquo; &ldquo;expect,&rdquo; &ldquo;may,&rdquo; &ldquo;plan,&rdquo;
 &ldquo;potential,&rdquo; &ldquo;will,&rdquo; and similar expressions, and are based on Adaptimmune&rsquo;s current beliefs and expectations.
Such statements are based only upon current expectations of Adaptimmune. Reliance should not be placed on forward-looking statements
because they involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially
from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product
development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory
and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ
materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you
to our Annual Report on Form&nbsp;10-K filed with the Securities and Exchange Commission for the year ended 31 December, 2023, our Quarterly
Reports on Form&nbsp;10-Q, Current Reports on Form&nbsp;8-K, and other filings with the Securities and Exchange Commission. The forward-looking
statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation
to update such forward-looking statements to reflect subsequent events or circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="tm2420733d1_ex99-1img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Dr.&nbsp;D&rsquo;Angelo
has financial interests related to Adaptimmune.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Adaptimmune Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Investor Relations</B><BR>
Juli P. Miller, Ph.D. - VP, Corporate Affairs and Investor Relations<BR>
T : +1 215 825 9310<BR>
M : +1 215 460 8920<BR>
<U>Juli.Miller@adaptimmune.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Media Relations</B><BR>
Dana Lynch, Senior Director of Corporate Communications<BR>
M: +1 267 990 1217<BR>
<U>Dana.Lynch@adaptimmune.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>adap-20240801.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWamHybOdzZR+eYkxtmB9bVm6Hygq0AFl2yx/aY0mUasO -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:adap="http://adaptimmune.com/20240801" elementFormDefault="qualified" targetNamespace="http://adaptimmune.com/20240801">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://adaptimmune.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="adap-20240801_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="adap-20240801_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>adap-20240801_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>adap-20240801_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://adaptimmune.com/role/Cover" xlink:href="adap-20240801.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://adaptimmune.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm2420733d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2420733d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  N /L# 2(  A$! Q$!_\0
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M);9B3%DXYY/\JVM>\0-IOV:UT^V^VZE=\P0*< KW8GL*9XW /@S4\C_EF/\
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L$&J^)I9['H\4,(C:0>A8<_7K771QK#$D: A$4*H)SP/<T[FBB4W+<$DC_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140719377473872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  01,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-37368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ADAPTIMMUNE THERAPEUTICS PLC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001621227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">X0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">60 Jubilee Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Milton Park<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Abingdon, Oxfordshire<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">OX14 4RX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">1235 430000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing 6 Ordinary Shares, par value &#163;0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADAP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M ;IZNZ7?GEB5%=OHN;*P*2\.5YS!.^0&P/<+I>S[B=N9ES^L#/X#4$L#!!0
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ "3@"69E<G",0!@  G"<  !,
M             ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M"  ). )9)/I67XP$  !D$0  &               @($-"   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ "3@"69^@&_"Q @  X@P   T
M             ( !SPP  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  ). )9
MEXJ[',     3 @  "P              @ &K#P  7W)E;',O+G)E;'-02P$"
M% ,4    "  ). )9JL0B%C,!   B @  #P              @ &4$   >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ "3@"620>FZ*M    ^ $  !H
M         ( !]!$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ "3@"6660>9(9 0  SP,  !,              ( !V1(  %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  (Q0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2420733d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adaptimmune.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>adap-20240801.xsd</File>
    <File>adap-20240801_lab.xml</File>
    <File>adap-20240801_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2420733d1_8k.htm">tm2420733d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2420733d1_8k.htm": {
   "nsprefix": "adap",
   "nsuri": "http://adaptimmune.com/20240801",
   "dts": {
    "schema": {
     "local": [
      "adap-20240801.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "adap-20240801_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "adap-20240801_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2420733d1_8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://adaptimmune.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-08-01",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2420733d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-08-01",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2420733d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001104659-24-085098-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-24-085098-xbrl.zip
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MDS4&DA-VJEU#T6'9Y,,B#0H5V!\X9E0AZ!#C.J-ED>),IN?GFV+_E^*#I96
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MP401KWCM6ZQX14<J((A2K$<6/<>%T>%$Q8'C><Y$/9ERTQLC%I5?\K&1 T<
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MI=[VNZKK^SK4B9?I0'5GLR2^\<)Z+1ZIP[<7[P<.IJ'G?QHG<1X%33\.X^1
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M]9I/0BDI) YDMI4CD.]QX,VQP C2#(++ZIHX#GC1_20? \RIB4R:0>\03VY
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MIST&^4#U+]3[BP$G2(JDPJ,9!.BF:@I!K<@@K#T:CB_^^Z2O/G:OWI^^__%
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M2QV-O3']8>C,RQ_P,;E8W/?SF8OM49[3Y\IDKEA.<ZJ,Q#,S2D/0J["U;^9
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MJZT?22-Y<S[^!2?9-1=B64$%D.I4SJ1QC)]H:K0\::-TW4<B22S5R>!L7?&
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M,C R-# X,#$N>'-D4$L! A0#%     @ "3@"696,[4/]"@  @(8  !4
M         ( !6 ,  &%D87 M,C R-# X,#%?;&%B+GAM;%!+ 0(4 Q0    (
M  DX EE"@E-D6 <  -M7   5              "  8@.  !A9&%P+3(P,C0P
M.# Q7W!R92YX;6Q02P$"% ,4    "  ). )9@KE]ZC$6  !^;@  $@
M        @ $3%@  =&TR-#(P-S,S9#%?.&LN:'1M4$L! A0#%     @ "3@"
M68YN/NB<'P  YID  !8              ( !="P  '1M,C0R,#<S,V0Q7V5X
>.3DM,2YH=&U02P4&      4 !0!) 0  1$P

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>tm2420733d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="adap-20240801.xsd" xlink:type="simple"/>
    <context id="AsOf2024-08-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001621227</identifier>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-01</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-08-01" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-08-01" id="Fact000004">0001621227</dei:EntityCentralIndexKey>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-08-01" id="xdx2ixbrl0014">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:DocumentType contextRef="AsOf2024-08-01" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-08-01" id="Fact000010">2024-08-01</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-08-01" id="Fact000011">ADAPTIMMUNE THERAPEUTICS PLC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-08-01" id="Fact000012">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-08-01" id="Fact000013">1-37368</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-08-01" id="Fact000015">60 Jubilee Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2024-08-01" id="Fact000016">Milton Park</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-08-01" id="Fact000017">Abingdon, Oxfordshire</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-08-01" id="Fact000018">OX14 4RX</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="AsOf2024-08-01" id="Fact000019">GB</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="AsOf2024-08-01" id="Fact000020">44</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-08-01" id="Fact000021">1235 430000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-08-01" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-08-01" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-08-01" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-08-01" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2024-08-01" id="Fact000026">American Depositary Shares, each representing 6 Ordinary Shares, par value &#xa3;0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-08-01" id="Fact000027">ADAP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-08-01" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-08-01" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
